+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 14 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the efficacy and safety of EscharEx EX-03 5% formulation compared to a placebo in the treatment of Venous Leg Ulcers VLU. This study involves adults with VLU wounds between 2 cm and 25 cm in size, with wound duration from 4 weeks to 12 months. It aims to assess how well EscharEx helps with debridement and wound bed preparation. Participants will be randomly assigned to receive either EscharEx, a sterile powder containing proteolytic enzymes enriched in bromelain, or a placebo gel without the active enzyme. The powder is mixed with sterile water to form a gel that is applied to the wound area. The study includes several periods a screening period with two visits, a daily treatment period of up to eight daily applications over two weeks, followed by weekly wound management visits for up to 12 weeks, and an optional wound closure confirmation period of up to two weeks. After wound closure, participants enter a 12-week monthly visit period to monitor wound closure durability. During the study, participants undergo clinical assessments of wound debridement and closure, including visual evaluations after each application and over the follow-up periods. Researchers will measure the incidence of complete debridement, time to wound closure, and healthy tissue development. Safety and wound healing progress are monitored throughout. The total participation can last up to 29 weeks, with regular visits to ensure detailed monitoring of wound status and treatment effects.

Age: 18Years +All GendersPhase 3
60 locations
E

Actively Recruiting

Researchers are evaluating the clinical effectiveness and safety of icotrokinra in adults with moderately to severely active Crohns disease, a long-term condition causing serious inflammation in the intestines. The study is a Phase 2b3 randomized, double-blind, placebo-controlled trial aiming to better understand how well icotrokinra works in treating this condition. Participants will receive one of several oral treatments daily during an initial 12-week induction phase either one of two doses of icotrokinra or a matching placebo. After Week 12, their response status will guide further treatment. Those responding to icotrokinra may be randomized to maintenance doses for up to 40 weeks, with some eligible to join a long-term extension study. Placebo recipients who respond may continue placebo or switch to icotrokinra under specific conditions. Throughout the trial, participants will undergo regular assessments to monitor clinical response, remission, and endoscopic healing at Weeks 12 and 40. Safety will be closely followed up to four weeks after the last dose. The study measures various outcomes including patient-reported remission, inflammatory markers, quality of life, and fatigue. Total participation may extend up to several months depending on treatment phase and eligibility for long-term follow-up.

Age: 18Years +All GendersPhase 2Phase 3
395 locations
P

Actively Recruiting

Researchers are studying the effectiveness and safety of Afimkibart as an induction and maintenance treatment for people with moderately to severely active Crohns disease. This Phase III, multicenter, double-blind, placebo-controlled study aims to evaluate how well Afimkibart works compared to a placebo in managing this condition. Participants will be randomly assigned to receive either Afimkibart or a placebo. Those receiving Afimkibart will get an intravenous IV infusion followed by subcutaneous SC injections. The study includes two experimental groups receiving Afimkibart and one group receiving placebo, both administered by IV and SC methods. The treatment and follow-up period extends through 52 weeks to assess both induction and maintenance therapy effects. During the study, participants will undergo evaluations including the Crohns Disease Activity Index CDAI for clinical remission and endoscopic assessments at week 52. Additional measurements at week 12 and throughout the study include symptom tracking, stool frequency, abdominal pain, quality of life questionnaires, and monitoring of adverse events. The total study duration may extend up to 70 weeks for safety follow-up and outcome assessments.

Age: 16Years - 80YearsAll GendersPhase 3
375 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of tulisokibart in people with moderately to severely active Crohns disease. This program includes two separate studies Study 1, which involves both induction and maintenance treatment phases, and Study 2, which includes only the induction treatment phase. The main goals are to see if one or more doses of tulisokibart are better than placebo in achieving clinical remission according to specific Crohns Disease Activity Index scores or stool frequency and abdominal pain scores, and to assess endoscopic response at weeks 12 and 52 depending on the study and regulatory region. Participants receive tulisokibart either intravenously or subcutaneously at different dose levels depending on the study arm. Some receive a high dose induction followed by high or low dose maintenance, others receive low dose throughout, and some receive placebo. Extension arms allow participants who complete their original treatment to continue receiving high or low dose subcutaneous tulisokibart if they qualify. The study uses random assignment to treatment groups and is double-blind, meaning neither participants nor researchers know who receives the drug or placebo. Throughout the studies, participants undergo evaluations at specified weeks to measure clinical remission, clinical response, endoscopic response, and other outcomes such as fatigue and quality of life. Safety is monitored by tracking adverse events and discontinuations due to side effects. The overall participation may last up to 52 weeks for Study 1 and 12 weeks for Study 2, with assessments at multiple points to carefully observe treatment effects and safety.

Age: 16Years - 80YearsAll GendersPhase 3
499 locations
E

Actively Recruiting

Researchers are evaluating the efficacy of RO7837195 compared to a placebo in adults with moderately to severely active ulcerative colitis who have not responded well to conventional or advanced treatments. This Phase IIb study aims to assess how effective and safe RO7837195 is for these patients. The study is sponsored by Genentech, Inc. and uses a randomized, double-blind design to ensure reliable results. Participants will undergo a screening period lasting up to 5 weeks to determine eligibility. The main treatment includes a 12-week placebo-controlled induction phase, after which all participants receive RO7837195 during a 40-week active treatment extension. RO7837195 is given according to predefined dose regimens, and the study includes multiple experimental groups receiving different doses, as well as a group initially receiving placebo followed by RO7837195. Throughout the study, participants will have regular assessments to measure clinical remission at week 12, clinical response, endoscopic improvement, and safety through monitoring adverse events and blood levels of the drug. The studys total duration includes the screening, treatment phases, and a safety follow-up after the last dose, with outcome measures tracked up to week 65. Researchers will also monitor for the development of antibodies against RO7837195 to further understand treatment effects and safety.

Age: 18Years +All GendersPhase 2
111 locations
P

Actively Recruiting

Researchers are evaluating the drug PALI-2108 in adults with moderate to severe ulcerative colitis, a condition causing inflammation in the colon. This phase 2 study compares different doses of PALI-2108 against a placebo to assess how well the drug works, its safety, and how the body processes it. The study focuses on measuring clinical remission and endoscopic improvement to understand the drugs impact. Participants will receive either 15 mg or 30 mg of PALI-2108 once daily or a matching placebo. The treatment is given orally, and the study uses a randomized, double-blind design where neither participants nor researchers know which treatment is assigned. The study includes induction and maintenance therapy periods, with assessments at 12 weeks and up to 48 weeks to evaluate clinical response and remission. During the study, participants will undergo regular clinical evaluations including the modified Mayo Score assessments, endoscopic examinations, and monitoring for adverse effects. The primary outcome is the proportion of participants achieving clinical remission at Week 12. Secondary outcomes include clinical response and endoscopic improvements at Weeks 12 and 48. Participants safety and drug effects will be closely monitored throughout the study duration, which may last up to about two years from enrollment.

Age: 18Years - 75YearsAll GendersPhase 2
115 locations
S

Actively Recruiting

Researchers are studying afimkibart also known as RO7790121 to understand how it may affect the bodys processing of certain medicines that rely on cytochrome P450 enzymes in people with moderately to severely active ulcerative colitis UC. This Phase 1, open-label study focuses on the drug-drug interaction potential by observing changes in the pharmacokinetics of enzyme substrates used in medication metabolism. Participants will receive doses of afimkibart along with a cocktail of cytochrome P450 enzyme substrates, including drugs like midazolam, omeprazole, dextromethorphan, warfarin, and caffeine. The study includes a disease-drug-drug interaction phase followed by an optional long-term extension phase where participants may continue treatment and monitoring. During the study, participants will be monitored through blood tests measuring drug levels and enzyme activity up to approximately 13 weeks. Researchers will evaluate various pharmacokinetic outcomes such as drug concentration over time and metabolite ratios. Safety assessments, including adverse event tracking and serum concentration of afimkibart, will continue for up to 5 years, with the total study participation lasting several years depending on extension enrollment.

Age: 18Years - 60YearsAll GendersPhase 1
18 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of duvakitug in people with moderately to severely active Crohns Disease CD in a multinational, multicenter, randomized, double-blind, placebo-controlled Phase 3 study. This trial includes three sub-studies designed to assess treatment effects through different induction periods and includes a follow-up for some participants. Participants receive subcutaneous injections of either one of two doses of duvakitug or a placebo according to the study protocol. The study duration may last up to 35 weeks, including a screening period of up to 5 weeks, a 12-week induction period in each sub-study, and a 6-week follow-up period for those not entering maintenance. Participants who continue to the pivotal maintenance study have up to 8 or 15 scheduled visits depending on their sub-study. During the study, participants undergo regular assessments including clinical remission and endoscopic response measured by Crohns Disease Activity Index CDAI, Simple Endoscopic Score for Crohns Disease SES-CD, and patient-reported outcomes. Researchers also monitor safety through adverse event tracking, serum drug levels, and antibody formation. The primary outcomes focus on remission and response at 12 weeks, with additional secondary outcomes and safety evaluations throughout the study.

Age: 16Years - 80YearsAll GendersPhase 3
461 locations
S

Actively Recruiting

Healthy Volunteer

Metabolic syndrome is a condition that increases the risk of cardiovascular disease and type 2 diabetes, particularly affecting young adults. This observational, cross-sectional case-control study focuses on young women aged 18 to 35 years to explore the relationship between serum asprosin levels, specific circulating microRNAs, and metabolic syndrome components. The study aims to identify potential new biomarkers that could help in early diagnosis and improve understanding of metabolic syndrome in this population. Participants are divided into two groups women with metabolic syndrome who meet specific diagnostic criteria and healthy age-matched controls. Each participant attends a single study visit where fasting blood samples are collected to measure asprosin, brain-derived neurotrophic factor BDNF, cortisol, and six selected microRNAs, along with routine blood tests. Additional assessments include body measurements, blood pressure, and validated questionnaires covering physical activity, diet, sleep quality, stress, and quality of life. During the 90-minute visit, participants undergo blood collection, body composition analysis using bioelectrical impedance, and complete several questionnaires. Researchers evaluate various metabolic and health-related indices, such as insulin resistance and lipid profiles, to compare both groups. The primary outcomes are serum asprosin concentration and microRNA expression, with secondary measures including body fat, metabolic scores, and psychological assessments. All participants receive their individual results, and data is anonymized for analysis.

Age: 18Years - 35YearsFEMALE
1 location
S

Actively Recruiting

Researchers are evaluating the effects of intravenous ferric carboxymaltose FCM compared with a placebo on death risk, heart failure events, NT-proBNP levels, and quality of life in patients who recently had an acute myocardial infarction AMI and have iron deficiency. This phase 4, multicenter, randomized, double-blind, placebo-controlled clinical trial aims to assess these outcomes over a follow-up period ranging from 8 to 36 months. Participants are randomly assigned to receive either an intravenous 15-minute infusion of 1000 mg FCM diluted in saline or a placebo infusion of saline alone. The first dose is given on the day of randomization, with follow-up visits at 4, 8, 12, 18, 24, and 30 months to reassess participants and possibly repeat treatment if safety criteria are met. During the study, participants undergo evaluations including monitoring of death rates, heart failure events such as unplanned hospitalizations or emergency visits, changes in NT-proBNP concentration, and quality of life measured by the EQ-5D questionnaire. Safety and treatment effects are tracked throughout the follow-up period, which can last up to 36 months from the start of participation.

Age: 18Years - 90YearsAll GendersPhase 4
43 locations

1-10 of 14

1